Capabilities by Region

Greenhill is active in all major markets with meaningful corporate advisory activity, including in North America, Europe,  Asia, and Australia.

Recent Transactions

22-Jun-15
$640 million
United States flag
Target: 

28-property portfolio of independent living senior housing properties from affiliates of Holiday Retirement, an entity controlled by Fortress Investment Group

United States flag
Acquiror: 
New Senior Investment Group Inc.

Provided Fairness Opinion to the Transaction Committee of the Board of Directors of New Senior Investment Group, a $2.5 billion publicly traded REIT, on its acquisition of a 28-property portfolio from Holiday Retirement, one of the largest private operators of senior housing in the US

14-Jun-15
$912 million
United States flag
Target: 

Niska Gas Storage Partners

Canada flag
Acquiror: 
Brookfield Infrastructure Group

Advised the Conflicts Committee of the Board of Directors of Niska and provided a fairness opinion on its sale to Brookfield

08-Jun-15
$45 million
Canada flag
Target: 

Aralez Pharmaceuticals Inc.

Canada flag
Acquiror: 
QLT Inc.

Advised QLT Inc. on its strategic equity investment in Aralez Pharmaceuticals Inc., a newly formed global specialty pharmaceutical company resulting from the business combination of POZEN Inc. and Tribute Pharmaceuticals Canada Inc., and the special distribution of the Aralez shares to QLT shareholders.

04-Jun-15
$1.5 billion
Australia flag
Target: 

Moorebank Intermodal Terminal Project

Australia flag
Acquiror: 
Qube / Aurizon

Advised the Australian Government on the public-private partnership with a consortium comprising Qube (ASX: QUB) and Aurizon (ASX:AZJ) to develop and operate a A$1.9 billion import /export and interstate intermodal terminal as well as associated warehousing and rail infrastructure in Moorebank, Sydney

02-Jun-15
$NA
United Kingdom flag
Target: 

Portfolio of GlaxoSmithKline plc consumer and OTC brands

United States flag
Acquiror: 
Perrigo Company plc

Advised GlaxoSmithKline plc, a leading British pharmaceutical company, on the disposal of a portfolio of consumer and OTC brands to Omega Pharma NV, a subsidiary of Perrigo Company plc

Pages

show all